Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks. The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.
Conditions Studied
Interventions
- DRUG Disitamab vedotin
Study Locations (20)
California
- Los Angeles Cancer Network — Anaheim
- Los Angeles Cancer Network — Fountain Valley
- Los Angeles Hematology Oncology Medical Group — Glendale
- Los Angeles Cancer Network — Los Angeles
- Valkyrie Clinical Trials — Los Angeles
- Mission Community Hospital (Satellite Site) — Los Angeles
- Clinical and Translational Research Unit (CTRU) — Palo Alto
- Stanford Cancer Center — Palo Alto
- Stanford Women's Cancer Center — Palo Alto
- Stanford Health Care, Investigational Drug Service — Stanford
- Los Angeles Hematology Oncology Medical Group — Van Nuys
Colorado
- Rocky Mountain Cancer Centers, LLP — Aurora
- Rocky Mountain Cancer Centers, LLP — Boulder
- Rocky Mountain Cancer Centers, LLP — Centennial
- Rocky Mountain Cancer Centers, LLP — Colorado Springs
Alabama
- Southern Cancer Center, PC — Daphne
- Southern Cancer Center, PC — Foley
- Southern Cancer Center, PC — Mobile
Arizona
- Banner Gateway Medical Center — Gilbert
- Banner MD Anderson Cancer Center — Gilbert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2030-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06966453
The ClinicalTrials.gov registry entry for NCT06966453 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which Disitamab vedotin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06966453 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Colorado, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06966453 about?
NCT06966453 is a clinical study titled "A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer". The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have br...
What is the current status of trial NCT06966453?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-06-30. Estimated completion is 2030-01-27.
What conditions does trial NCT06966453 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06966453?
The interventions under investigation include: Disitamab vedotin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06966453?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06966453 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.